Cardiovascular manifestations in inflammatory rheumatic diseases;Kardiovaskuläre manifestationen bei entzündlich rheumatischen erkrankungen

Wiener Medizinische Wochenschrift

Volumn 152, Issue 9-10, 2002, Pages 220-222

  Niksic, F ^a   Burmucic, K ^a   Kullich, W ^a   Klein, G ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Atherosclerosis; Cardiovascular mortality; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; HUMAN; INFLAMMATION; MORTALITY; RHEUMATIC DISEASE; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CAUSE OF DEATH; CORONARY ARTERIOSCLEROSIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; T-LYMPHOCYTES;

EID: 0036263552     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-258X.2002.01117.x     Document Type: Article

References (32)

1. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis
2. Shattuck lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
3. Hyperhomocysteinemia: An independent risk factor for vascular disease
4. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?
5. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
6. Production of C-reactive protein and risk of coronary events in stable and unstable angina
7. The prognostic value of C-reactive protein and serum amyloid A in severe unstable angina
8. Monoclonal t-cell proliferation and plaque instability in acute coronary syndromes
9. Cardiovascular mortality in women with rheumatoid arthritis
10. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study
11. Inflammation-mediated rheumatic diseases and atherosclerosis
12. Cardiac involvement in systemic lupus erythematosus
13. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention
14. Statins and the acute-phase response
15. Is atherosclerosis a complication of long-term corticosteroid treatment?
16. A tale of two diseases - Atherosclerosis and rheumatoid arthritis
17. Coronary artery disease risk factors in the Johns Hopkins lupus cohort: Prevalence, recognition by patients, and preventive practices
18. Risk factors for coronary artery disease in patients with systemic lupus erythematosus
19. Long-term effects of pravastatin on plasma concentration of C-reactive protein
20. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
21. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
22. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
23. Atherosclerosis - An inflammatory disease
24. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell α-actin in early atherosclerotic lesions
25. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries
26. Extra-articular rheumatoid arthritis: Prevalence and mortality
27. The bimodal mortality pattern of systemic lupus erythematosus
28. Survival and cause of death in rheumatoid arthritis: A 25-year prospective follow up
29. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden
30. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset
31. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: An 8 week randomized placebo controlled trial
32. The mortality of rheumatoid arthritis